Open Orphan #ORPH – £5m Influenza human challenge study contract win
Open Orphan (AIM: ORPH), a rapidly growing specialist contract research organisation (CRO) and world leader in vaccine and antiviral testing using human challenge clinical trials, announces that hVIVO, a subsidiary of Open Orphan plc, has signed a £5m influenza human challenge study contract with a biotech company developing an antiviral drug for protection against respiratory […]
Open Orphan #ORPH – £5.1m RSV Human Challenge Study Contract Win
Open Orphan (AIM: ORPH), a rapidly growing specialist contract research organisation (CRO) and world leader in vaccine and antiviral testing using human challenge clinical trials , announces that hVIVO , a subsidiary of Open Orphan, has signed a £5.1m contract with a biopharmaceutical company to test its Investigational Medicinal Product (IMP) using hVIVO’s respiratory syncytial […]
New York Times – Would You Let a Scientist Infect You With COVID?
By Kate Murphy, New York Times In an age of masking, compulsive hand sanitizing and plexiglass dividers, it seems inconceivable that for more than 40 years people enthusiastically signed up — and were often put on a waiting list — to have respiratory viruses, including coronaviruses, dripped into their noses. They were volunteers at the […]
Open Orphan #ORPH – Major year-on-year revenue growth and profitable H1 2021 performance following a year of turnaround and transition in 2020
Open Orphan (AIM: ORPH), a rapidly growing specialist contract research organisation (CRO) and a world leader in vaccine and antiviral testing using human challenge clinical trials, announces its unaudited interim results for the six months ended 30 June 2021. These results show a continued pattern of profitability from Q4 2020 to a firmly profitable position […]
Open Orphan #ORPH – £5.7m Influenza human challenge study contract win
Open Orphan (AIM: ORPH), a rapidly growing specialist clinical research organisation (CRO) and world leader in vaccine and antiviral testing using human challenge clinical trials, announces that hVIVO, a subsidiary of Open Orphan plc, has signed a £5.7m contract with a specialist biotechnology company developing therapeutics for respiratory viral infections, to test its antiviral product […]
Researchers Infect Volunteers With Coronavirus, Hoping to Conquer Covid-19 – Wall Street Journal
By Jenny Strasburg Sept. 4, 2021 530 am ET LONDON—Much of the world spent the past year taking vaccines and wearing masks to evade Covid-19. In the U.K., almost four dozen volunteers have had the virus dripped into their noses by syringe in clinical experiments. So-called human challenge studies—which intentionally expose healthy people to viruses […]
WSJ – Researchers Ready Lab-Grown Covid-19 Delta Variant for Human Trials
U.K. company is growing the highly contagious variant under tight lab controls for use in challenge studies Scientists have coaxed the Delta strain to mature, said Andrew Catchpole, chief scientiic oficer of trial partner hVivo. PHOTO: HVIVO SERVICES LIMITED by Jenny Strasburg – Wall Street Journal LONDON—While the rest of the world is trying to […]
Open Orphan #ORPH – £8.1m Asthma Human Challenge Study Contract Win
Open Orphan (AIM: ORPH), a rapidly growing specialist contract research organisation (CRO) and world leader in vaccine and antiviral testing using human challenge clinical trials, announces that hVIVO, a subsidiary of Open Orphan plc, has signed an £8.1m contract with a major global pharmaceutical company to test its inhaled human rhinovirus (hRV) antiviral product using […]
Open Orphan #ORPH – Development of Controlled Human Malaria Infection Human Challenge Study
Open Orphan plc (AIM: ORPH), a rapidly growing specialist clinical research organisation (CRO) and world leader in testing vaccines and antivirals using human challenge clinical trials, announces that its subsidiary, hVIVO, has developed a Controlled Human Malaria Infection (“CHMI”) challenge model, both strengthening and further diversifying the Company’s world leading portfolio of viral challenge study models. […]
Open Orphan #ORPH – Pfizer successful Phase 2a human challenge trial
Rapid progress at Open Orphan #ORPH. In Pfizer’s recent quarterly update, CEO Albert Bourla, noted (on page 5) that one of the key highlights of Pfizer’s Q2 was the “Successful Phase 2a human challenge trial with RSV Adult vaccine candidate”. Although Pfizer have not mentioned Open Orphan by name and we have not formally announced […]